IP Library Granted Patent US 11,219,634
Granted Patent B2
US 11,219,634 · App. 15/545,302 · Granted Jan 11, 2022

Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells

Inventors: Mary G. Prieve (Lake Forest Park, WA); Michael E. Houston, Jr. (Kirkland, WA); Pierrot Harvie (Seattle, WA); Sean D. Monahan (Lake Forest Park, WA)
Assignee: Genevant Sciences GmbH
A61K31/7105A61K9/0019A61K9/1075A61K9/1272A61K9/5123A61K31/40A61K31/407A61K31/47A61K31/475A61K31/4745A61K31/5365A61K31/704A61K31/7048A61K47/186A61K47/32A61K48/0041C08F293/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,219,634
App. No.
15/545,302
Granted
Jan 11, 2022
Kind
B2
Abstract

Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.

Claims (35)

1. A pH-sensitive, membrane-destabilizing polymer of formula V:

T1-L-[PEGMA m -M2 n ] v -[DMAEMA q -PAA r -BMA s ] w   V

wherein

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units;

M2 is butyl methacrylate residue or hexyl methacrylate residue;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, wherein m is greater than n and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is a first targeting ligand comprising an N-acetylgalactosamine (NAG) residue; and

L is a linking moiety comprising a polyethylene glycol (PEG) moiety.

2. The polymer of claim 1 , wherein M2 is hexyl methacrylate residue.

3. The polymer of claim 1 , wherein PEGMA is polyethyleneglycol methacrylate residue having 4-5 ethylene glycol units or 7-8 ethylene glycol units.

4. The polymer of claim 1 , wherein the linking moiety L comprises a polyethylene glycol (PEG) moiety having 2-20 ethylene glycol units.

5. The polymer of claim 1 , wherein the polymer of formula V is

NAG-PEG 12 -[PEGMA300 m -HMA n ] v -[D q -P r -B s ] w   Vi,

wherein

PEG 12 is a linking moiety comprising a polyethylene glycol having 12 ethylene glycol units;

HMA is hexyl methacrylate residue;

B is a butyl methacrylate residue (BMA);

P is a propyl acrylic acid residue (PAA); and

D is a dimethylaminoethyl methacrylate residue (DMAEMA).

6. The polymer of claim 5 , wherein m is 0.7 to 0.85.

7. The polymer of claim 5 , wherein n is 0.15 to 0.3.

8. The polymer of claim 5 , wherein s is 0.5 to 0.65.

9. The polymer of claim 5 , wherein v is 2.5 to 7 kDa.

10. The polymer of claim 5 , wherein w is 4 to 7 kDa.

11. The polymer of claim 5 , wherein q is 0.25 to 0.4.

12. The polymer of claim 5 , wherein r is 0.07 to 0.15.

Assignments (3)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 3, 2020
From: GENEVANT SCIENCES LTD.
To: ROIVANT SCIENCES LTD.
Reel/Frame 052312/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2018
From: PHASERX, INC.
To: ROIVANT HEPATOLOGY GMBH
Reel/Frame 047649/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2018
From: ROIVANT HEPATOLOGY GMBH
To: GENEVANT SCIENCES GMBH
Reel/Frame 047689/0406 →
Continuity (4)
Provisional Application 62106024 · Jan 21, 2015
Provisional Application 62173847 · Jun 10, 2015
Provisional Application 62233568 · Sep 28, 2015
Related Publication 20180221402A1 · Aug 9, 2018
Cited By (5)
US 12,343,405 US 12,551,573 US 12,553,037 US 12,559,743 US 12,594,349